2023 World Conference on Lung Cancer (Posters)-EP11.03. Incidence of Cardiotoxicity in Patients Treated for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors

EP11.03. Incidence of Cardiotoxicity in Patients Treated for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to determine the incidence of cardiotoxicity in patients with non-small cell lung cancer (NSCLC) who were treated with immune checkpoint inhibitors (ICPis). The study found that although the majority of patients were white, black and mixed race patients experienced a higher rate of cardiotoxic events. The study also found a high rate of QTc prolongation, which could be influenced by the use of other medications that prolong QTc intervals. However, the incidence of QTc prolongation may be underestimated due to the lack of baseline electrocardiograms for most patients.<br /><br />The study had a small sample size and did not include a comparator arm, which are limitations of the study. The researchers suggest that there is a need for stronger monitoring guidelines and increased awareness of the potential for ICPi-associated cardiotoxicity in NSCLC. Further research is needed to analyze the differences in outcomes based on different racial and ethnic groups.<br /><br />Lung cancer is one of the most common types of cancer, accounting for a significant number of cancer diagnoses. ICPis have become the standard of care for various types of lung cancer. However, they can lead to immune-related adverse events, including cardiovascular events, which can be fatal. Current guidelines recommend managing these events with high-dose corticosteroids.<br /><br />The study found that 50.7% of the patients experienced cardiotoxic events, with arrhythmias and QTc prolongation being the most common. Four deaths were attributed to cardiac arrest. The study also found that a large proportion of patients had baseline cardiovascular comorbidities, but only a portion of them had a recommended baseline electrocardiogram.<br /><br />In conclusion, this study highlights the incidence of cardiotoxicity in NSCLC patients treated with ICPis and the need for better monitoring and awareness. Further research is needed to understand the differences in outcomes among different racial and ethnic groups.

Asset Subtitle

Luis Raez

Meta Tag

Speaker Luis Raez

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

cardiotoxicity

non-small cell lung cancer

immune checkpoint inhibitors

QTc prolongation

incidence

racial and ethnic groups

arrhythmias

cardiac arrest

monitoring guidelines

baseline electrocardiograms